Summary:
NLS Pharmaceutics Ltd has submitted three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), with two focusing on sleep-related conditions. One abstract presents preclinical findings on dual orexin receptor agonists (AEX-41 and AEX-2) for narcolepsy, showing wake-promoting properties without the metabolic side effects of traditional stimulants. Another abstract explores a multitarget pharmacological approach to managing diabetes-related neurological and sleep disorders, integrating neuropeptides and metabolic modulators to address circadian rhythm disruption. The third abstract examines the potential of Mazindol ER for fentanyl dependence. NLS Pharmaceutics emphasizes its commitment to advancing treatments for sleep disorders, addiction, and cognitive health.
Key Takeaways:
- Preclinical Research on Narcolepsy Treatment – AEX-41 and AEX-2, two dual orexin receptor agonists, demonstrated wake-promoting effects in a mouse model of narcolepsy, offering potential benefits without stimulant-like metabolic risks.
- Addressing Sleep Disorders in Diabetes – Another abstract introduces a multitarget strategy aimed at improving sleep and neurological health in patients with diabetes, focusing on circadian rhythm regulation.
- Expanding Therapeutic Research – NLS Pharmaceutics also investigates Mazindol ER’s potential as a therapeutic for fentanyl dependence.
Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd announced the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), including studies on dual orexin receptor agonists for narcolepsy and a multitarget strategy for diabetes-related sleep disorders.
NLS Pharamceuticals’ abstracts:
- “Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy” presents promising preclinical findings on AEX-41 and AEX-2, two novel dual orexin receptor agonists, in a mouse model of narcolepsy. In preliminary conclusion, these compounds exhibit wake-promoting properties without the adverse metabolic effects associated with traditional stimulants, making them strong candidates for treating narcolepsy and related hypersomnolence disorders.
- The abstract “Comprehensive Multitarget Strategy for Managing Diabetes-Associated Neurological and Sleep Disorders (DANS)” introduces a pharmacological platform for treating diabetes-related cognitive and sleep disorders. The research integrates dual orexin receptor agonists, neuropeptide-based preconditioning, and metabolic modulators to address the interplay between neuroinflammation, β-cell dysfunction, and circadian rhythm disruption.
- The third abstract, “Evaluating the Effects of Mazindol on Fentanyl Dependence in Animal Models (Study KO-943),” explores the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity on 5-HT1A, MOP, and OX2R receptors, for fentanyl dependence. Preclinical data will demonstrate its ability to mitigate reward-seeking behavior and withdrawal symptoms, positioning it as a promising non-opioid alternative for managing fentanyl addiction.
“NLS Pharmaceutics is honored to contribute to the 2025 ASCP Annual Meeting, one of the premier global platforms for advancing clinical research in neuropsychopharmacology,” says Eric Konofal, MD, PhD, chief scientific officer of NLS Pharmaceutics, in a release. “Our research spans innovative therapeutic solutions such as Mazindol ER for fentanyl dependence, dual orexin receptor agonists for narcolepsy, and a multitarget approach to managing diabetes-related neurological and sleep disorders. These abstracts reflect our commitment to addressing critical unmet medical needs in addiction medicine, sleep disorders, and cognitive health.”
The ASCP Annual Meeting, taking place from May 27-30, 2025, in Scottsdale, Ariz, is dedicated to advancing research in neuropsychopharmacology. This event provides a platform for research and innovative therapeutic approaches in neuropsychiatric drug development, precision psychiatry, and addiction medicine.
ID 12409580 © BrunoWeltmann | Dreamstime.com
